Cycle Group Holdings Limited finalized its acquisition of Applied Therapeutics, Inc. on February 3 2026, paying $14.3 million in equity and offering $0.088 in cash per share to Applied shareholders. The deal also includes a contingent value right that could pay up to $0.40 per share if govorestat, Applied’s lead Aldose Reductase Inhibitor, meets predefined milestones. The transaction was funded entirely from Cycle’s cash on hand and was structured as a tender offer followed by a merger that will delist Applied from Nasdaq and terminate its SEC reporting obligations.
The acquisition aligns with Cycle’s stated focus on rare metabolic diseases. CEO James Harrison said the deal “expands our portfolio in a therapeutic area where we have a strong track record and where there are no approved treatments.” Govorestat targets classic galactosemia, Charcot‑Marie‑Tooth sorbitol dehydrogenase deficiency, and phosphomannomutase‑2 congenital disorder of glycosylation—conditions that fit squarely within Cycle’s rare‑disease strategy. By adding govorestat, Cycle gains a CNS‑penetrant candidate that could accelerate its pipeline and provide new revenue streams.
Applied Therapeutics entered the deal in a financially distressed state. As of September 30 2025, the company held $11.9 million in cash, had negative shareholder equity of $561 thousand, and no debt. Its market capitalization had fallen to $15.7 million, a decline of more than 80 % over the previous year. The acquisition gives Applied access to Cycle’s resources and capital, while Cycle acquires a candidate that has already progressed through early‑stage development and regulatory review.
Govorestat’s development has faced regulatory hurdles. In November 2024, the FDA issued a Complete Response Letter for the classic galactosemia application, citing objectionable conditions observed during an inspection. Applied was preparing to discuss next steps for the Charcot‑Marie‑Tooth indication in late 2025. The new ownership will allow Cycle to address these regulatory challenges with additional expertise and funding.
The transaction was announced as a tender offer that was extended to February 2 2026 and closed on February 3 2026. Shareholders received cash and a CVR, and the merger will result in Applied’s delisting and the termination of its public reporting. The deal structure reflects Cycle’s confidence in govorestat’s potential while providing Applied with a clear exit path amid its limited financial runway.
Implications for Cycle include a broadened rare‑disease pipeline and the ability to leverage its existing infrastructure to advance govorestat’s clinical program. For investors, the acquisition signals Cycle’s commitment to expanding in a high‑need therapeutic area, while Applied’s shareholders receive a premium over the market price and a path to liquidity. The deal also underscores the importance of financial health and regulatory readiness in the biopharma sector, as Applied’s distressed position and govorestat’s regulatory setbacks were key factors in the transaction’s structure and valuation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.